The metabolic syndrome as a risk factor for venous and arterial thrombosis

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 5, 2009, Pages 451-457

  Dentali, Francesco ^a   Squizzato, Alessandro ^a   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Arterial thrombosis; Metabolic syndrome; Venous thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTERY THROMBOSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; METABOLIC SYNDROME X; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; WAIST CIRCUMFERENCE;

ADULT; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; THROMBOSIS; VENOUS THROMBOSIS;

EID: 70449442756     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1234140     Document Type: Review

References (72)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 285 (19) 2486-2497
2. Reaven G M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988 37 (12) 1595-1607
3. Alberti K G., Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998 15 (7) 539-553
4. Alberti K G., Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndromea new worldwide definition. Lancet 2005 366 (9491) 1059-1062 (Pubitemid 41338752)
5. Grundy S M., Cleeman J I., Daniels S R. et al, American Heart Association National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 112 (17) 2735-2752
6. Park Y W., Zhu S, Palaniappan L, Heshka S, Carnethon M R., Heymsfield S B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 19881994. Arch Intern Med 2003 163 (4) 427-436 (Pubitemid 36241019)
7. Lakka H M., Laaksonen D E., Lakka T A. et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002 288 (21) 2709-2716
8. Balkau B, Charles M A., Drivsholm T et al, European Group for the Study of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002 28 (5) 364-376
9. Dallongeville J, Cottel D, Ferrières J et al. Household income is associated with the risk of metabolic syndrome in a sex-specific manner. Diabetes Care 2005 28 (2) 409-415
10. Bataille V, Perret B, Dallongeville J et al. Metabolic syndrome and coronary heart disease risk in a population-based study of middle-aged men from France and Northern Ireland. A nested case-control study from the PRIME cohort. Diabetes Metab 2006 32 (5 Pt 1) 475-479
11. Assmann G, Guerra R, Fox G et al. Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. Am J Cardiol 2007 99 (4) 541-548
12. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome in urban Asian Indian adultsa population study using modified ATP III criteria. Diabetes Res Clin Pract 2003 60 (3) 199-204
13. Ko G T., Cockram C S., Chow C C. et al. High prevalence of metabolic syndrome in Hong Kong Chinesecomparison of three diagnostic criteria. Diabetes Res Clin Pract 2005 69 (2) 160-168
14. Arai H, Yamamoto A, Matsuzawa Y et al. Prevalence of metabolic syndrome in the general Japanese population in 2000. J Atheroscler Thromb 2006 13 (4) 202-208
15. Ford E S., Giles W H., Mokdad A H. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004 27 (10) 2444-2449
16. Flegal K M., Carroll M D., Ogden C L., Johnson C L. Prevalence and trends in obesity among US adults, 19992000. JAMA 2002 288 (14) 1723-1727
17. Alexander C M., Landsman P B., Grundy S M. The influence of age and body mass index on the metabolic syndrome and its components. Diabetes Obes Metab 2008 10 (3) 246-250
18. Goodman E, Dolan L M., Morrison J A., Daniels S R. Factor analysis of clustered cardiovascular risks in adolescence: obesity is the predominant correlate of risk among youth. Circulation 2005 111 (15) 1970-1977
19. Daniels S R., Arnett D K., Eckel R H. et al. Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation 2005 111 (15) 1999-2012
20. Raynaud E, Pérez-Martin A, Brun J, Aïssa-Benhaddad A, Fédou C, Mercier J. Relationships between fibrinogen and insulin resistance. Atherosclerosis 2000 150 (2) 365-370
21. Ford E S. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003 168 (2) 351-358
22. Yudkin J S., Juhan-Vague I, Hawe E et al, The HIFMECH Study Group. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 2004 53 (7) 852-857
23. Duncan B B., Schmidt M I., Chambless L E., Folsom A R., Carpenter M, Heiss G. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adultsthe ARIC study. Atherosclerosis Risk in Communities. Obes Res 2000 8 279-286
24. Carvalho de Sousa J, Bruckert E, Giral P et al. Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity. Haemostasis 1989 19 (3) 125-130
25. Grant P J. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007 262 (2) 157-172
26. Mineo C, Deguchi H, Griffin J H., Shaul P W. Endothelial and antithrombotic actions of HDL. Circ Res 2006 98 (11) 1352-1364
27. Shimomura I, Funahashi T, Takahashi M et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996 2 (7) 800-803
28. Alessi M C., Bastelica D, Mavri A et al. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003 23 (7) 1262-1268
29. Marchesini G, Brizi M, Morselli-Labate A M. et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999 107 (5) 450-455
30. Banfi C, Mussoni L, Risé P et al. Very low density lipoprotein-mediated signal transduction and plasminogen activator inhibitor type 1 in cultured HepG2 cells. Circ Res 1999 85 (2) 208-217
31. Festa A, Williams K, Tracy R P., Wagenknecht L E., Haffner S M. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 2006 113 (14) 1753-1759
32. Ingelsson E, Pencina M J., Tofler G H. et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 2007 116 (9) 984-992
33. Godsland I F., Crook D, Proudler A J., Stevenson J C. Hemostatic risk factors and insulin sensitivity, regional body fat distribution, and the metabolic syndrome. J Clin Endocrinol Metab 2005 90 (1) 190-197
34. Trovati M, Mularoni E M., Burzacca S et al. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 1995 44 (11) 1318-1322
35. Ferreira I A., Mocking A I., Feijge M A. et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006 26 (2) 417-422
36. Doggen C J., Smith N L., Lemaitre R N., Heckbert S R., Rosendaal F R., Psaty B M. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004 24 (10) 1970-1975
37. Englyst N A., Taube J M., Aitman T J., Baglin T P., Byrne C D. A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes 2003 52 (5) 1248-1255
38. Jarvis G E., Atkinson B T., Snell D C., Watson S P. Distinct roles of GPVI and integrin alpha(2)beta(1) in platelet shape change and aggregation induced by different collagens. Br J Pharmacol 2002 137 (1) 107-117
39. Lyon C J., Law R E., Hsueh W A. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003 144 (6) 2195-2200
40. Haffner S M., Miettinen H, Mykkänen L, Karhapää P, Rainwater D L., Laakso M. Leptin concentrations and insulin sensitivity in normoglycemic men. Int J Obes Relat Metab Disord 1997 21 (5) 393-399 (Pubitemid 27190192)
41. Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999 48 (2) 426-429
42. Ozata M, Avcu F, Durmus O, Yilmaz I, Ozdemir I C., Yalcin A. Leptin does not play a major role in platelet aggregation in obesity and leptin deficiency. Obes Res 2001 9 (10) 627-630
43. Blake G J., Ridker P M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003 41 (4 suppl S) 37S-42S
44. Nickenig G. Should angiotensin II receptor blockers and statins be combined? Circulation 2004 110 (8) 1013-1020
45. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001 7 (8) 941-946
46. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon M J. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003 278 (45) 45021-45026
47. Ouchi N, Kihara S, Funahashi T et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003 107 (5) 671-674
48. Kato H, Kashiwagi H, Shiraga M et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Thromb Vasc Biol 2006 26 (1) 224-230
49. Elbatarny H S., Netherton S J., Ovens J D., Ferguson A V., Maurice D H. Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: implication in obesity-associated cardiovascular diseases. Eur J Pharmacol 2007 558 (1-3) 7-13
50. Thomas G N., Chook P, Qiao M et al. Deleterious impact of high normal glucose levels and other metabolic syndrome components on arterial endothelial function and intima-media thickness in apparently healthy Chinese subjects: the CATHAY study. Arterioscler Thromb Vasc Biol 2004 24 (4) 739-743
51. Kim J A., Montagnani M, Koh K K., Quon M J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006 113 (15) 1888-1904
52. Montagnani M, Golovchenko I, Kim I et al. Inhibition of phosphatidylinositol 3-kinase enhances mitogenic actions of insulin in endothelial cells. J Biol Chem 2002 277 (3) 1794-1799
53. McNeill A M., Rosamond W D., Girman C J. et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005 28 (2) 385-390
54. Gami A S., Witt B J., Howard D E. et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007 49 (4) 403-414
55. Schillaci G, Pirro M, Vaudo G et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004 43 (10) 1817-1822
56. Tong P C., Kong A P., So W Y. et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Programs Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007 30 (5) 1206-1211
57. McNeill A M., Katz R, Girman C J. et al. Metabolic syndrome and cardiovascular disease in older people: the cardiovascular health study. J Am Geriatr Soc 2006 54 (9) 1317-1324
58. Milionis H J., Rizos E, Goudevenos J, Seferiadis K, Mikhailidis D P., Elisaf M S. Components of the metabolic syndrome and risk for first-ever acute ischemic nonembolic stroke in elderly subjects. Stroke 2005 36 (7) 1372-1376 (Pubitemid 40967496)
59. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005 36 (7) 1366-1371
60. Kurl S, Laukkanen J A., Niskanen L et al. Metabolic syndrome and the risk of stroke in middle-aged men. Stroke 2006 37 (3) 806-811
61. Ageno W, Prandoni P, Romualdi E et al. The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost 2006 4 (9) 1914-1918
62. Ambrosetti M, Ageno W, Salerno M, Pedretti R F., Salerno-Uriarte J A. Metabolic syndrome as a risk factor for deep vein thrombosis after acute cardiac conditions. Thromb Res 2007 120 (6) 815-818
63. Ay C, Tengler T, Vormittag R et al. Venous thromboembolisma manifestation of the metabolic syndrome. Haematologica 2007 92 (3) 374-380
64. Ray J G., Lonn E, Yi Q et al, HOPE-2 investigators. Venous thromboembolism in association with features of the metabolic syndrome. QJM 2007 100 (11) 679-684
65. Prandoni P, Bilora F, Marchiori A et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003 348 (15) 1435-1441
66. Becattini C, Agnelli G, Prandoni P et al. A prospective study on cardiovascular events after acute pulmonary embolism. Eur Heart J 2005 26 (1) 77-83
67. Prandoni P, Ghirarduzzi A, Prins M H. et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost 2006 4 (9) 1891-1896 (Pubitemid 44226764)
68. Hansson P O., Eriksson H, Welin L, Svärdsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: the study of men born in 1913 Arch Intern Med 1999 159 (16) 1886-1890
69. Samama M M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000 160 (22) 3415-3420
70. Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen P W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008 117 (1) 93-102
71. Ray J G., Mamdani M, Tsuyuki R T., Anderson D R., Yeo E L., Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001 161 (11) 1405-1410
72. Ramcharan A S., Van Stralen K J., Snoep J D., Mantel-Teeuwisse A K., Rosendaal F R., Doggen C J. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009 7 (4) 514-520